CymitQuimica logo

CAS 1792180-81-4

:

Ritlecitinib

Description:
Ritlecitinib is a small molecule drug that functions as a selective inhibitor of Janus kinase (JAK) enzymes, specifically targeting JAK1 and JAK3. This compound is primarily investigated for its therapeutic potential in treating autoimmune diseases, particularly rheumatoid arthritis and alopecia areata. Ritlecitinib's mechanism of action involves modulating the immune response by inhibiting the signaling pathways that contribute to inflammation and immune dysregulation. The substance is characterized by its ability to penetrate tissues effectively, which is crucial for its efficacy in targeting systemic conditions. In terms of pharmacokinetics, Ritlecitinib exhibits a favorable absorption profile, with a half-life that supports once-daily dosing. Safety and tolerability profiles are essential considerations in its clinical development, as with any JAK inhibitor, due to potential side effects such as increased risk of infections or changes in blood parameters. Ongoing clinical trials continue to evaluate its effectiveness and safety in various patient populations, contributing to the understanding of its role in modern therapeutic regimens.
Formula:C15H19N5O
Synonyms:
  • 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one
  • 2-Propen-1-one, 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-
  • 1-[(2S,5R)-2-methyl-5(7H-pyrrolo[2,3-d]pyrimidine-4-ylamino)-1-piperidinly]-2-propen-1-one malonate,PF06651600
  • PF-06651600;PF 06651600;PF06651600
  • Ritlecitinib
  • CS-2733
  • PF-06651600
  • EOS-61890
  • 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.